U.S. Rep. Earl Blumenauer questions FDA oversight of Elon Musk's Neuralink. Recent reports reveal FDA concerns about quality control at Neuralink's facilities, raising doubts about human trials. Blumenauer urges FDA action, citing past violations and rushed experiments.
Qraft Technologies’ AI Risk Indicator has pointed to a risk level of 22 for the week of Nov. 7, in the "cautious" range, an increase from the risk level of 13 recorded the prior week.
